Abstract
Purpose: To investigate the potential influence of long non-coding RNA (lncRNA) TUG1 on the development of endometrial cancer (EC).Methods: A total of 24 paired EC species and paracancerous species were collected, and the differential expressions of TUG1 in them were determined. The regulatory effects of TUG1 on proliferative and migratory potential in Ishikawa and HEC-1A cells were assessed using cell counting kit-8 (CCK-8) and Transwell assay, respectively. Potential protein binding TUG1 was predicted by bioinformatics analysis and subsequently verified using RIP (RNA-Binding Protein Immunoprecipitation) assay. Rescue experiments were conducted to uncover the mechanism of TUG1 in regulating the development of EC.Results: TUG1 was highly expressed in EC species and cell lines. Higher levels of TUG1 was observed in EC patients with metastases than those without metastatic cancer (p < 0.05). Overexpression of TUG1 markedly facilitated proliferative and migratory potential in EC cells. Taurine-upregulated gene 1 (TUG1) directly bound Fragile X-related protein 1 (FXR1) and positively regulated its level (p < 0.05). Through interaction with FXR1, TUG1 stimulated the malignant development of EC.Conclusion: LncRNA TUG1 is upregulated in EC species, which facilitates proliferative and migratory potentials in EC cells by interacting with FXR1.
Highlights
Endometrial cancer (EC) is a malignant tumor that is frequently found in the female reproductive system
Taurine-upregulated gene 1 (TUG1) was highly expressed in EC species (Figure 1 A)
Both protein and mRNA levels of Fragile X-related protein 1 (FXR1) were upregulated in HEC1A cells overexpressing TUG1 (Figure 3 A and B)
Summary
Endometrial cancer (EC) is a malignant tumor that is frequently found in the female reproductive system. Its incidence is second only to cervical cancer. It is reported that approximately 320,000 women are diagnosed with EC, and 76,000 die of EC annually [1]. The incidence of EC ranks first place in reproductive tract malignancies. The incidence of EC amongst the younger people is on the increase in developing countries [2]. Most EC patients are diagnosed in the early stage through screening and symptoms of abnormal vaginal bleeding. Therapeutic efficacy for advanced, recurrent and metastatic EC is far from satisfactory
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
